stockrowWarby Parker Inc.
WRBY Healthcare Medical Instruments & Supplies
Warby Parker Inc.’s revenue for fiscal 2025 (year ended December 2025) was $871.9 million, up 13.0% from fiscal 2024.
- Revenue
- +10.4%
- EPS
- −20.0%
- Free cash flow
- −30.3%
Quarter to September 2026, against a year earlier
Follow WRBY
Alert me
Warby Parker Inc. (WRBY) Free cash flow margin
Warby Parker Inc.'s free cash flow margin over the twelve months to 30 September 2026 was 2.28%, down 2.7 percentage points from fiscal 2025 (5.02%). Over the past ten years it has ranged from −14.9% (fiscal 2021) to 5.02% (fiscal 2025) — the current reading is the highest in ten years. That is in line with the Medical Instruments & Supplies industry median of 2.36% and above the Healthcare sector median of 0.00%.
Free cash flow margin, annual
Embed this chart
Annual newest first
| Period | Free cash flow margin | Change (points) |
|---|---|---|
| FY2025 | 5.02% | 0.52 |
| FY2024 | 4.50% | 3.41 |
| FY2023 | 1.09% | 9.42 |
| FY2022 | −8.33% | 6.56 |
| FY2021 | −14.9% | (18.11) |
| FY2020 | 3.22% | 6.25 |
| FY2019 | −3.03% | — |
Against its own ten years
Free cash flow margin against peers
| Company | Free cash flow margin |
|---|---|
| LMAT LeMaitre Vascular, Inc. compare | 24.9% |
| ICUI ICU Medical, Inc. compare | 12.5% |
| ATRC AtriCure, Inc. compare | 8.98% |
| XRAY DENTSPLY SIRONA Inc. compare | 7.61% |
| WRBY Warby Parker Inc. | 2.28% |
| AZTA Azenta, Inc. compare | 1.61% |
| STVN Stevanato Group S.p.A. compare | −0.61% |
| KMTS Kestra Medical Technologies, Ltd. compare | −115.3% |
| PLSE Pulse Biosciences, Inc compare | −14,462.5% |
| Medical Instruments & Supplies industry median | 2.36% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Free cash flow margin is
Free Cash Flow Margin tells an investor how much of each sale turns into cash the company keeps after paying for investment in its assets.
(Operating Cash Flow + Property, Plant, Equipment Change (Net) + Intangible Assets Change (Net)) ÷ Revenue
More on WRBY
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement